| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/05/2013 | US20130323285 Peptide adjuvants |
| 12/05/2013 | US20130323283 Compositions and methods for treating foxp3+ treg related diseases |
| 12/05/2013 | US20130323282 Compositions and methods |
| 12/05/2013 | US20130323281 Ordered flagellin array as an immunostimulant |
| 12/05/2013 | US20130323280 Methods for preparing vesicles and formulations produced therefrom |
| 12/05/2013 | US20130323279 Human Endogenous Retrovirus Polypeptide Compositions and Methods of Use Thereof |
| 12/05/2013 | US20130323278 Chimeric Flavivirus Vaccines |
| 12/05/2013 | US20130323277 Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof |
| 12/05/2013 | US20130323276 Malaria vaccines based on pre-erythrocytic antigens from p. falciparum |
| 12/05/2013 | US20130323275 Methods and compositions for inducing a t-cell response to plasmodium species |
| 12/05/2013 | US20130323274 Escherichia coli immunogens with improved solubility |
| 12/05/2013 | US20130323273 Adipogenic Adenoviruses as a Biomarker for Disease |
| 12/05/2013 | US20130323272 Novel and powerful mhc-class ii peptides derived from survivin |
| 12/05/2013 | US20130323267 Highly concentrated anti-cd40 antibody pharmaceutical preparation |
| 12/05/2013 | US20130323266 Methods for treating cancer with notch2/3 antibodies |
| 12/05/2013 | US20130323265 Methods for treating cancer with dll4 antagonists |
| 12/05/2013 | US20130323264 Diagnostic and therapeutic uses of moesin fragments |
| 12/05/2013 | US20130323263 Sparc angiogenic domain and methods of use |
| 12/05/2013 | US20130323262 Methods and materials for treating inflammatory conditions |
| 12/05/2013 | US20130323261 Purified antibody composition |
| 12/05/2013 | US20130323260 Stabilized formulations containing anti-dll4 antibodies |
| 12/05/2013 | US20130323258 Compositions and methods for treating cardivascular disease |
| 12/05/2013 | US20130323254 Therapeutic anti-tirc7 antibodies for use in immune related and other diseases |
| 12/05/2013 | US20130323253 Xyxin fragment biomarker for diagnosis of colon cancer |
| 12/05/2013 | US20130323251 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
| 12/05/2013 | US20130323247 Treatment of acute lymphoblastic leukemia |
| 12/05/2013 | US20130323246 Use of mdl-1 antagonists to treat spondylarthropathy |
| 12/05/2013 | US20130323243 Filovirus fusion proteins and their uses |
| 12/05/2013 | US20130323242 Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| 12/05/2013 | US20130323239 Modulation of pilr receptors to treat sepsis |
| 12/05/2013 | US20130323232 Methods for the identification and treatment of patients sensitive to anti igf-1r inhbition therapy |
| 12/05/2013 | US20130323230 Treatment of myelosuppression |
| 12/05/2013 | US20130323204 Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy |
| 12/05/2013 | CA2875205A1 Therapeutic agent or prophylactic agent for dementia |
| 12/05/2013 | CA2875162A1 Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein |
| 12/05/2013 | CA2875131A1 Cladosporium peptides |
| 12/05/2013 | CA2875130A1 Alternaria peptides |
| 12/05/2013 | CA2874966A1 Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections |
| 12/05/2013 | CA2874780A1 Inflammation-enabling polypeptides and uses thereof |
| 12/04/2013 | EP2669367A1 A human dendritic cell line |
| 12/04/2013 | EP2669298A2 Single variable immunoglobulin domain comprising VL-DH-JL |
| 12/04/2013 | EP2669297A1 Humanized anti-egfr antibody l4-h3 and coding gene thereof |
| 12/04/2013 | EP2669294A1 Novel IL-3 antibodies and their use in diagnosis and treatment of diseases or malfunctions associated with elevated levels of IL-3 |
| 12/04/2013 | EP2668960A2 Compounds for treating cardiac damage after ischaemia/reperfusion |
| 12/04/2013 | EP2668959A1 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein |
| 12/04/2013 | EP2668211A1 Pharmaceutical compositions comprising human antibodies to pcsk9 |
| 12/04/2013 | EP2668209A1 Antibodies selective for cells presenting egfr at high density |
| 12/04/2013 | EP2668208A1 Cross-reactive staphylococcus aureus antibody |
| 12/04/2013 | EP2668207A1 Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
| 12/04/2013 | EP2668206A1 Engineering of immunoglobulin domains |
| 12/04/2013 | EP2668201A2 Immunological compositions comprising hiv gp41 polypeptide derivatives |
| 12/04/2013 | EP2667896A2 Methods and compositions for treating alzheimer's disease |
| 12/04/2013 | EP2667895A1 Use of at least one p75ntr receptor inhibitor, alone or in association with at least one trka receptor activator, or of at least one trka receptor activator, for the treatment of chronic inflammatory diseases |
| 12/04/2013 | EP2667894A1 Conjugates utilizing platform technology for stimulating immune response |
| 12/04/2013 | EP2667893A2 Advanced prime and boost vacinne |
| 12/04/2013 | EP2667892A1 Rsv immunization regimen |
| 12/04/2013 | EP2667891A1 Combination vaccines |
| 12/04/2013 | EP2667890A1 Cyaa-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
| 12/04/2013 | EP2667888A1 Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases |
| 12/04/2013 | EP2484757A9 Virus capable of expressing -galactose epitope, and method for production of vaccine |
| 12/04/2013 | CN1701121B Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| 12/04/2013 | CN103429737A Cytotoxicity-inducing therapeutic agent |
| 12/04/2013 | CN103429620A Stable heterodimeric antibody design with mutations in the Fc domain |
| 12/04/2013 | CN103429618A Antibodies against ROR1 and uses thereof |
| 12/04/2013 | CN103429611A Novel hemagglutinin 5 (H5) proteins for treatment and prevention of influenza infection |
| 12/04/2013 | CN103429265A Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of HCV infection |
| 12/04/2013 | CN103429264A Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| 12/04/2013 | CN103429263A Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| 12/04/2013 | CN103429262A Overcoming resistance to ERBB pathway inhibitors |
| 12/04/2013 | CN103429261A Modified antibody with improved half-life |
| 12/04/2013 | CN103429260A Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
| 12/04/2013 | CN103429259A Fluorocarbon-linked peptide formulation |
| 12/04/2013 | CN103429258A Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
| 12/04/2013 | CN103429252A Diagnostic and therapeutic uses of moesin fragments |
| 12/04/2013 | CN103429248A Cancer inhibiting agent, antibody production enhancing agent, and therapeutic agent for hepatitis |
| 12/04/2013 | CN103421843A Coded H5N1 subtype avian influenza virus synonymous hemagglutinin (HA) protein, gene of synonymous neuraminidase (NA) protein and application of HA and NA |
| 12/04/2013 | CN103421748A Porcine circovivus2 strain and application thereof |
| 12/04/2013 | CN103421746A Monoclonal antibody EEEV-5E4 resisting EEEV E2 protein, B-cell epitope peptide recognized by EEEV-5E4 as well as application of EEEV-5E4 and B-cell epitope peptide |
| 12/04/2013 | CN103421745A Monoclonal antibody EEEV-6E2 resisting EEEV E2 protein, B-cell epitope peptide recognized by EEEV-6E2 as well as application of EEEV-6E2 and B-cell epitope peptid |
| 12/04/2013 | CN103421744A Monoclonal antibody (EEEV-5F4) resisting EEEV I E2 protein, B-cell epitope peptide recognized by EEEV-5F4 as well as application of EEEVI-5F4 and B-cell epitope peptide |
| 12/04/2013 | CN103421738A Pharmacy applications of MTA1 and inhibitor thereof |
| 12/04/2013 | CN103421733A Haemophilus parasuis-swine cholera Salmonella bigeminy genetic engineering vaccine |
| 12/04/2013 | CN103421732A Attenuated vaccine of salmonella choleraesuis capable of expressing surface antigen of haemophilus parasuis |
| 12/04/2013 | CN103421731A Haemophilus parasuis attenuated salmonella vaccine |
| 12/04/2013 | CN103421729A Gene recombined swine cholera salmonella choleraesuis vaccine for blue-ear disease and application thereof |
| 12/04/2013 | CN103421728A Recombinant bordetella bronchiseptica strain, vaccine and use |
| 12/04/2013 | CN103421708A Strangles streptococcus strain XZ1 and application of strangles streptococcus strain XZ1 in strangles vaccine |
| 12/04/2013 | CN103421118A CTL epitope peptide of HTNV-Gn/Gc specificity and polymer and application thereof |
| 12/04/2013 | CN103421117A Immune-enhanced virus-like particles, expression vector thereof, and preparation and application thereof |
| 12/04/2013 | CN103421114A Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| 12/04/2013 | CN103421113A Anti-BLyS antibody |
| 12/04/2013 | CN103421112A Binding molecule capable of resisting enterovirus, and applications thereof |
| 12/04/2013 | CN103421106A Recombinant blomia tropicalis allergen Blot 5 protein, preparation method, and applications thereof |
| 12/04/2013 | CN103421095A Pig lysin mutant, and preparation method and application thereof |
| 12/04/2013 | CN103417980A Novel freeze-drying protective additive for duck virus hepatitis live vaccines |
| 12/04/2013 | CN103417968A Application of poly cytosine binding protein-2 inhibitor to prepare medicaments for treating human glioma |
| 12/04/2013 | CN103417967A Application of inhibitor of CXCL-10 in preparation of drug for treatment and/or prevention of lung injury |
| 12/04/2013 | CN103417965A Anti-VEGF antibody containing pharmaceutical composition |
| 12/04/2013 | CN103417964A Application of anti-VEGF antibody |
| 12/04/2013 | CN103417963A Optimized preparation method of micro-encapsulation oral inactivated vaccines of escherichia coli |